Developer docs
API playgroundTry for free, no card

Search company profiles

PeriPharm

Full company profile

uuid00vq5gn

Namestring
PeriPharm
Websiteurl
peripharm.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

PeriPharm is a privately held, Montréal-based consulting firm founded in 2003 that delivers pharmacoeconomics, health outcomes research, and market access services to companies developing healthcare innovations. The firm operates with a small team of 11-50 employees and presents itself as a specialist provider in the health economics and outcomes research (HEOR) domain, addressing the reimbursement, payer, and evidence-generation needs of pharma, biotech, and medical device innovators rather than running a generalist consulting practice.

The firm's core offering centers on analytical and advisory work tied to market access and reimbursement strategy. This typically encompasses health technology assessment (HTA) submissions, cost-effectiveness and budget-impact modeling, real-world evidence synthesis, and payer value communications for innovative therapies and devices. The underlying "product" is therefore expert analytical labor and codified methodology rather than a software platform; no proprietary technology stack, AI/ML components, or productized tooling are disclosed in the source data. There are no patents, trademarks, certifications, app assets, or API/SDK products referenced, consistent with a pure-services delivery model.

Commercially, PeriPharm operates as a fee-for-service professional services firm, with project-based engagements and likely retainer relationships with sponsors preparing for market entry, HTA review, or post-launch evidence generation. No pricing model, contract values, customer logos, distribution channels, or partnership arrangements are disclosed, and the company website returned only a loading/verification page rather than substantive content. The firm has no disclosed funding rounds, M&A activity, or strategic transactions, consistent with a bootstrapped, owner-operated professional services model that has sustained itself organically since founding.

Short descriptiontext

PeriPharm is a privately held Montréal-based consulting firm founded in 2003 that provides pharmacoeconomics, health outcomes research, and market access services to healthcare innovators, operating with a small team of 11-50 employees.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMontreal, Canada
HQ citystring
Montreal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
pharmacoeconomics consulting, health outcomes research, market access consulting, healthcare economic evaluation, pharmaceutical pricing analysis
Industry2 codes
PRIMARYHLAEAKAK
Pharmacy Benefit Analytics, Reporting & Employer Consulting
SECONDARYHLAEAKAA
Formulary Management & Clinical Pharmacy Programs
NAICS code1 code
  • Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds524292
Product category
Pharmacoeconomic & Market Access Consulting
Social media profiles1 record
Cost components3 values
Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

PeriPharm provides pharmacoeconomics, health outcomes research, and market access consulting services for healthcare innovations. The firm supports pharmaceutical and healthcare organizations in demonstrating the economic and clinical value of their products and navigating access to reimbursement and formulary decisions.

Differentiator
Functional benefit
Problem solved
Product and service3 records
1Pharmacoeconomics Consulting
CategoryHealth Economics Consulting
Description

Economic evaluation of pharmaceuticals and healthcare interventions, including cost-effectiveness analysis, budget impact modeling, and pricing studies for pharma, biotech, and medical device clients.

2Health Outcomes Research
CategoryHealth Economics & Outcomes Research (HEOR)
Description

Real-world evidence and outcomes research services to support clinical and economic value demonstration of healthcare innovations for payer and HTA submissions.

3Market Access Consulting
CategoryMarket Access & Reimbursement Consulting
Description

Strategy and evidence support to help healthcare innovators achieve reimbursement, formulary listing, and successful uptake of new products in target markets.

No data
Peers8 records
TypeBroad incumbent
Description

Global CRO and life sciences data platform with a large HEOR, real-world evidence, and market access consulting practice. Competes with PeriPharm for pharma HEOR and market access mandates, but at much larger scale across the full clinical-commercial lifecycle.

TypeEmerging player
Description

Boutique market access and pricing consultancy for pharma and biotech. Similar in scale and value proposition to PeriPharm, with overlapping focus on pricing, reimbursement, and value communications.

3Trinity Partners
TypeDirect peer
Description

Life sciences consulting firm with strong focus on market access, pricing, and commercial strategy for biopharma. Comparable to PeriPharm on market access and value demonstration work, with a similar boutique, senior-staffed model.

TypeBroad incumbent
Description

Global CRO with a dedicated commercial and outcomes services arm offering HEOR, market access, and pricing/reimbursement consulting. Comparable to PeriPharm on outcomes research and market access, but with a much broader portfolio spanning clinical to commercial.

TypeBroad incumbent
Description

Economic and strategy consulting firm with a life sciences practice covering HEOR, market access, and pricing. Comparable to PeriPharm on HEOR and market access work, but as part of a broader management consulting platform.

TypeDirect peer
Description

Market access, pricing, and HEOR consulting business serving pharma and biotech. Directly comparable to PeriPharm's market access and pharmacoeconomics offerings, with similar boutique-to-mid-size positioning.

TypeDirect peer
Description

Economic and financial consulting firm with a large health economics and outcomes research practice. Directly competes with PeriPharm on pharmacoeconomics and health outcomes research engagements for pharma, biotech, and medical device clients.

TypeDirect peer
Description

Dedicated HEOR, market access, and real-world evidence consulting business now part of Thermo Fisher's PPD. Directly competes with PeriPharm on pharmacoeconomics, evidence synthesis, and payer engagement services for pharma and biotech clients.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PeriPharm

Pharmacoeconomic & Market Access Consultingperipharm.com

PeriPharm is a privately held Montréal-based consulting firm founded in 2003 that provides pharmacoeconomics, health outcomes research, and market access services to healthcare innovators, operating with a small team of 11-50 employees.

What PeriPharm does

PeriPharm is a privately held, Montréal-based consulting firm founded in 2003 that delivers pharmacoeconomics, health outcomes research, and market access services to companies developing healthcare innovations. The firm operates with a small team of 11-50 employees and presents itself as a specialist provider in the health economics and outcomes research (HEOR) domain, addressing the reimbursement, payer, and evidence-generation needs of pharma, biotech, and medical device innovators rather than running a generalist consulting practice.

The firm's core offering centers on analytical and advisory work tied to market access and reimbursement strategy. This typically encompasses health technology assessment (HTA) submissions, cost-effectiveness and budget-impact modeling, real-world evidence synthesis, and payer value communications for innovative therapies and devices. The underlying "product" is therefore expert analytical labor and codified methodology rather than a software platform; no proprietary technology stack, AI/ML components, or productized tooling are disclosed in the source data. There are no patents, trademarks, certifications, app assets, or API/SDK products referenced, consistent with a pure-services delivery model.

Commercially, PeriPharm operates as a fee-for-service professional services firm, with project-based engagements and likely retainer relationships with sponsors preparing for market entry, HTA review, or post-launch evidence generation. No pricing model, contract values, customer logos, distribution channels, or partnership arrangements are disclosed, and the company website returned only a loading/verification page rather than substantive content. The firm has no disclosed funding rounds, M&A activity, or strategic transactions, consistent with a bootstrapped, owner-operated professional services model that has sustained itself organically since founding.

PeriPharm firmographics

Firmographics
Name
PeriPharm
Website
https://peripharm.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Short description
PeriPharm is a privately held Montréal-based consulting firm founded in 2003 that provides pharmacoeconomics, health outcomes research, and market access services to healthcare innovators, operating with a small team of 11-50 employees.
Ownership category
akta.pro rank

PeriPharm industry classification

Industry
Product category
Pharmacoeconomic & Market Access Consulting
NAICS
Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292)
akta.pro industry
PRIMARYHLAEAKAK
Pharmacy Benefit Analytics, Reporting & Employer Consulting
SECONDARYHLAEAKAA
Formulary Management & Clinical Pharmacy Programs

Keywords

  • Pharmacoeconomics consulting
  • Health outcomes research
  • Market access consulting
  • Healthcare economic evaluation
  • Pharmaceutical pricing analysis

Where PeriPharm is headquartered

Location

Headquarters

HQ city
Montreal
HQ country
Canada
HQ region
North America

Markets served

PeriPharm business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales

PeriPharm product offering

Product offering

Core offering

PeriPharm provides pharmacoeconomics, health outcomes research, and market access consulting services for healthcare innovations. The firm supports pharmaceutical and healthcare organizations in demonstrating the economic and clinical value of their products and navigating access to reimbursement and formulary decisions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmacoeconomics Consulting Economic evaluation of pharmaceuticals and healthcare interventions, including cost-effectiveness analysis, budget impact modeling, and pricing studies for pharma, biotech, and medical device clients.
  • Health Outcomes Research Real-world evidence and outcomes research services to support clinical and economic value demonstration of healthcare innovations for payer and HTA submissions.
  • Market Access Consulting Strategy and evidence support to help healthcare innovators achieve reimbursement, formulary listing, and successful uptake of new products in target markets.

Companies that use PeriPharm

Customer profile

Ideal customer profiles1 record

PeriPharm technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

PeriPharm competitors and assessment

Company assessment

Broad incumbents

  • IQVIA: Global CRO and life sciences data platform with a large HEOR, real-world evidence, and market access consulting practice. Competes with PeriPharm for pharma HEOR and market access mandates, but at much larger scale across the full clinical-commercial lifecycle.
  • ICON plc: Global CRO with a dedicated commercial and outcomes services arm offering HEOR, market access, and pricing/reimbursement consulting. Comparable to PeriPharm on outcomes research and market access, but with a much broader portfolio spanning clinical to commercial.
  • Charles River Associates (CRA) Life Sciences Practice: Economic and strategy consulting firm with a life sciences practice covering HEOR, market access, and pricing. Comparable to PeriPharm on HEOR and market access work, but as part of a broader management consulting platform.

Emerging players

  • Wickenstones: Boutique market access and pricing consultancy for pharma and biotech. Similar in scale and value proposition to PeriPharm, with overlapping focus on pricing, reimbursement, and value communications.

Direct peers

  • Trinity Partners: Life sciences consulting firm with strong focus on market access, pricing, and commercial strategy for biopharma. Comparable to PeriPharm on market access and value demonstration work, with a similar boutique, senior-staffed model.
  • Analysource (now Putnam Associates / Inizio Advisory): Market access, pricing, and HEOR consulting business serving pharma and biotech. Directly comparable to PeriPharm's market access and pharmacoeconomics offerings, with similar boutique-to-mid-size positioning.
  • Analysis Group: Economic and financial consulting firm with a large health economics and outcomes research practice. Directly competes with PeriPharm on pharmacoeconomics and health outcomes research engagements for pharma, biotech, and medical device clients.
  • Evidera (PPD/Thermo Fisher): Dedicated HEOR, market access, and real-world evidence consulting business now part of Thermo Fisher's PPD. Directly competes with PeriPharm on pharmacoeconomics, evidence synthesis, and payer engagement services for pharma and biotech clients.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

PeriPharm social profiles

Digital presence

PeriPharm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PeriPharm leadership team

Management profile

Number of profiles

PeriPharm funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PeriPharm M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PeriPharm

What does PeriPharm do?

PeriPharm provides pharmacoeconomics, health outcomes research, and market access consulting services for healthcare innovations. The firm supports pharmaceutical and healthcare organizations in demonstrating the economic and clinical value of their products and navigating access to reimbursement and formulary decisions.

Is PeriPharm a public or private company?

PeriPharm is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was PeriPharm founded?

PeriPharm was founded in 2003. It employs 11 to 50 people.

Where is PeriPharm based?

PeriPharm is headquartered in Montreal, Canada, in the North America region.

Who are PeriPharm's main competitors?

Broad incumbents on record are IQVIA, ICON plc and Charles River Associates (CRA) Life Sciences Practice. Wickenstones is listed as an emerging player. Direct peers are Trinity Partners, Analysource (now Putnam Associates / Inizio Advisory), Analysis Group and Evidera (PPD/Thermo Fisher).

Does PeriPharm have an API?

No public API is recorded for PeriPharm.

What industry is PeriPharm in?

PeriPharm's product category is Pharmacoeconomic & Market Access Consulting. Its primary akta.pro industry code is HLAEAKAK, Pharmacy Benefit Analytics, Reporting & Employer Consulting, with a secondary code of HLAEAKAA, Formulary Management & Clinical Pharmacy Programs. Its NAICS code is 524292.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NewswireDuchesnay and PeriPharm emphasize the need to update regulatory and reimbursement policies to improve access to innovations in women's healthDuchesnay and PeriPharm published a study in the Journal of Obstetrics and Gynaecology Canada showing Canadian women wait over three years for women's health medications. Of 45 FDA-approved women's health drugs from 2003-2023, only 24 were approved in Canada, and fewer than two-thirds are reimbursed by public plans.BioSpaceDuchesnay and PeriPharm emphasize the need to update regulatory and reimbursement policies to improve access to innovations in women’s healthDuchesnay and PeriPharm published a study in the Journal of Obstetrics and Gynaecology Canada on barriers to women's health innovations. The analysis of 20 years of data found that only 24 of 45 FDA-approved women's health medications were approved in Canada, and it takes over three years for a new drug to appear on a public formulary. The authors call for updated regulatory and reimbursement policies to improve access.PR NewswireA joint study by Duchesnay and PeriPharm exposes critical gaps in access to innovative women's health products in CanadaDuchesnay and PeriPharm released a joint study revealing significant gaps in access to innovative women's health products in Canada, finding that only 24 of 45 FDA-approved women's health products (53%) received Health Canada approval by July 2024, with just 13 publicly reimbursed. The research uncovered that the process for obtaining public coverage for women's health medications takes one year longer than general medication timelines and can exceed three years, suggesting the current HTA framework may not adequately capture the value of women's health innovations. The findings are intended to inform a position paper to be developed by leading experts by year end.